Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications. / Gawalko, Monika; Agbaedeng, Thomas A.; Saljic, Arnela; Mueller, Dominik N.; Wilck, Nicola; Schnabel, Renate; Penders, John; Rienstra, Michiel; van Gelder, Isabelle; Jespersen, Thomas; Schotten, Ulrich; Crijns, Harry J. G. M.; Kalman, Jonathan M.; Sanders, Prashanthan; Nattel, Stanley; Dobrev, Dobromir; Linz, Dominik.
I: Cardiovascular Research, Bind 118, Nr. 11, 2022, s. 2415–2427.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Gut microbiota, dysbiosis and atrial fibrillation. Arrhythmogenic mechanisms and potential clinical implications
AU - Gawalko, Monika
AU - Agbaedeng, Thomas A.
AU - Saljic, Arnela
AU - Mueller, Dominik N.
AU - Wilck, Nicola
AU - Schnabel, Renate
AU - Penders, John
AU - Rienstra, Michiel
AU - van Gelder, Isabelle
AU - Jespersen, Thomas
AU - Schotten, Ulrich
AU - Crijns, Harry J. G. M.
AU - Kalman, Jonathan M.
AU - Sanders, Prashanthan
AU - Nattel, Stanley
AU - Dobrev, Dobromir
AU - Linz, Dominik
PY - 2022
Y1 - 2022
N2 - Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF.
AB - Recent preclinical and observational cohort studies have implicated imbalances in gut microbiota composition as a contributor to atrial fibrillation (AF). The gut microbiota is a complex and dynamic ecosystem containing trillions of microorganisms, which produces bioactive metabolites influencing host health and disease development. In addition to host-specific determinants, lifestyle-related factors such as diet and drugs are important determinants of the gut microbiota composition. In this review, we discuss the evidence suggesting a potential bidirectional association between AF and gut microbiota, identifying gut microbiota-derived metabolites as possible regulators of the AF substrate. We summarize the effect of gut microbiota on the development and progression of AF risk factors, including heart failure, hypertension, obesity, and coronary artery disease. We also discuss the potential anti-arrhythmic effects of pharmacological and diet-induced modifications of gut microbiota composition, which may modulate and prevent the progression to AF. Finally, we highlight important gaps in knowledge and areas requiring future investigation. Although data supporting a direct relationship between gut microbiota and AF are very limited at the present time, emerging preclinical and clinical research dealing with mechanistic interactions between gut microbiota and AF is important as it may lead to new insights into AF pathophysiology and the discovery of novel therapeutic targets for AF.
KW - Arrhythmia
KW - Atrial fibrillation
KW - Cardiometabolic
KW - Gut microbiota
KW - Metabolites
KW - TRIMETHYLAMINE-N-OXIDE
KW - LIFE-STYLE INTERVENTION
KW - BILE-ACID METABOLISM
KW - INTESTINAL MICROBIOTA
KW - HEART-FAILURE
KW - L-CARNITINE
KW - DIET
KW - INFLAMMATION
KW - ANTIBIOTICS
KW - OVERWEIGHT
U2 - 10.1093/cvr/cvab292
DO - 10.1093/cvr/cvab292
M3 - Review
C2 - 34550344
VL - 118
SP - 2415
EP - 2427
JO - Cardiovascular Research
JF - Cardiovascular Research
SN - 0008-6363
IS - 11
ER -
ID: 317957921